

研究・業績

英語論文のみ

2018年

1. Higashihara E, Horie S, Kinoshita M, Harris PC, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K : A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. *Clin Exp Nephrol* 22(2) : 395-404, 2018.
2. Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K : Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. *Low Urin Tract Symptoms*. 10(2) : 148-152, 2018.
3. Fujita N, Tambo M, Terado Y, Fujita M, Okegawa T, Nutahara K : Vesicoenteric Fistula Arising from an Adenocarcinoma of Ectopic Pancreatic Tissue in a Meckel Diverticulum. *Case Rep Oncol* 11(1) : 6-10, 2018.
4. Narita M, Kageyama S, Okegawa T, Kinoshita H, Sato F, Nakagawa K, Habuchi T, Hoshi A, Matsubara A, Yoshimura K, Terachi T, Mimata H, Kawauchi A : Urological laparoendoscopic single-site and reduced port surgery: A nationwide survey in Japan. *Int J Urol* 25(3) : 263-268, 2018.
5. Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K : AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. *Prostate* 78(8) : 576-582, 2018.
6. Kinjo M, Yoshimura Y, Kitagawa Y, Okegawa T, Nutahara K : Sexual activity and quality of life in Japanese pelvic organ prolapse patients after transvaginal mesh surgery. *J Obstet Gynaecol Res* 2018 Apr 19. doi: 10.1111/jog.13654.
7. Yamaguchi T, Higashihara E, Okegawa T, Miyazaki I, Nutahara K : Optimal equation for estimation glomerular filtration rate in autosomal dominant polycystic kidney disease: Influence of tolvaptan. *Clin Exp Nephrol* 2018. (inpress)
8. Aizawa N, Watanabe D, Fukuhara H, Fujimura T, Kume H, Homma Y, Igawa Y. Inhibitory effects of silodosin on the bladder mechanosensitive afferent activities and their relation with bladder myogenic contractions in male rats with bladder outlet obstruction. *Neurourol Urodyn*. 2018, in press.
9. Akiyama Y, Niimi A, Nomiya A, Yamada Y, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Igawa Y and Homma Y. Extent of Hunner lesions: the relationships with symptom severity and clinical parameters in patients with Hunner-type interstitial cystitis. *Neurourol Urodyn*. 2018, in press.

10. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Nakagawa T, Kume H, Igawa Y, Homma Y. Predictors of Early Continence after Robot-assisted Radical Prostatectomy. *Low Urin Tract Symptoms*. 2018, in press.
11. Niimi A, Igawa Y, Aizawa N, Honma T, Nomiya A, Akiyama Y, Kamei J, Fujimura T, Fukuhara H and Homma Y. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. *Neurourol Urodyn*. 2018, in press.
12. Arakawa K, Hata K, Yamamoto Y, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Yoshida M, Fukuhara H, Fujishiro M, Morikawa T, Yamasoba T, Koike K, Fukayama M, Watanabe T. Nine primary malignant neoplasms-involving the esophagus, stomach, colon, rectum, prostate, and external ear canal-without microsatellite instability: a case report. *BMC Cancer* 18, 24, 2018.

2017 年

13. Shimizu F, Muto S, Taguri M, Ieda T, Tsujimura A, Sakamoto Y, Fujita K, Okegawa T, Yamaguchi R, Horie S : Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis. *Int J Urol* 24(5) : 367-372, 2017.
14. Okegawa T, Morimoto M, Nishizawa S, Kitazawa S, Honda K, Araki H, Tamura T, Ando A, Satomi Y, Nutahara K, Hara T : Intratumor heterogeneity in primary kidney cancer revealed by metabolic profiling of multiple spatially separated samples within tumors. *EBioMedicine*. 19:31-38, 2017.
15. Sato F, Nakagawa K, Kawauchi A, Matsubara A, Okegawa T, Habuchi T, Yoshimura K, Hoshi A, Kinoshita H, Miyajima A, Naitoh Y, Inoue S, Itaya N, Narita S, Hanai K, Okubo K, Yanishi M, Matsuda T, Terachi T, Mimata H : Laparoendoscopic single-site surgeries: A multicenter experience of 469 cases in Japan. *Int J Urol* 24(1) : 69-74, 2017.
16. Fujita N, Tambo M, Okegawa T, Higashihara E, Nutahara K : Distinguishing testicular torsion from torsion of the appendix testis by clinical features and signs in patients with acute scrotum. *Res Rep Urol* 9 : 169-174, 2017.
17. Yoshida H, Higashihara E, Maruyama K, Nutahara K, Nitatori T, Miyazaki I, Shiokawa Y : Relationship between intracranial aneurysms and the severity of autosomal dominant polycystic kidney disease. *Acta Neurochir* 159(12) : 2325-2330, 2017.
18. Miyakawa J, Taguchi S, Suzuki M, Endo K, Nose Y, Sato T, Ishikawa A, Fukuhara H, Homma Y. Impact of monthly 120 mg denosumab on bone metabolism in bone-metastatic prostate cancer undergoing androgen deprivation therapy. *Asian Pacific Journal of Cancer Care* 2, 55-60, 2017.
19. Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Preoperative chronic

- kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer. *World J Urol.* 36, 249-256, 2017.
20. Aizawa N, Ichihara K, Fukuhara H, Fujimura T, Andersson KE, Homma Y, Igawa Y. Characteristics of the mechanosensitive bladder afferent activities in relation with microcontractions in male rats with bladder outlet obstruction. *Sci Rep.* 7, 7646, 2017.
 21. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Miyazaki H, Nakagawa T, Kume H, Igawa Y, Homma Y. Overactive bladder is a negative predictor of achieving continence after robot-assisted radical prostatectomy. *Int J Urol.* 24, 749-756, 2017.
 22. Nakagawa T, Taguchi S, Kanatani A, Kawai T, Ikeda M, Urakami S, Matsumoto A, Komemushi Y, Miyakawa J, Yamada D, Suzuki M, Enomoto Y, Nishimatsu H, Kondo Y, Nagase Y, Hirano Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Oncological Outcome of Metastasectomy for Urothelial Carcinoma: Who is the Best Candidate? *Annals of Surgical Oncology* 24, 2794-2800, 2017.
 23. Fujimura T, Fukuhara H, Taguchi S, Yamada Y, Sugihara T, Nakagawa T, Niimi A, Kume H, Igawa Y, Homma Y. Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy. *BMC Cancer* 17, 454, 2017.
 24. Sugihara T, Yasunaga H, Matsui H, Nagao G, Ishikawa A, Fujimura T, Fukuhara H, Fushimi K, Ohori M, Homma Y. Accessibility to surgical robot technology and prostate-cancer patient behavior for prostatectomy. *Jpn J Clin Oncol.* 47, 647-651, 2017.
 25. Nakagawa T, Komemushi Y, Kawai T, Otsuka M, Miyakawa J, Uemura Y, Kanatani A, Taguchi S, Naito A, Suzuki M, Nishimatsu H, Hirano Y, Tanaka Y, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study. *World J Urol.* 35, 1569-1575, 2017.
 26. Sugiyama R, Aizawa N, Ito H, Fujimura T, Suzuki M, Nakagawa T, Fukuhara H, Kume H, Homma Y, Igawa Y. Synergic Suppressive Effect of Silodosin and Imidafenacin on Non-Voiding Bladder Contractions in Male Rats with Subacute Bladder Outlet Obstruction. *Low Urin Tract Symptoms.* 9, 94-101, 2017.
 27. Yamada Y, Fujimura T, Fukuhara H, Sugihara T, Takemura K, Kakutani S, Suzuki M, Nakagawa T, Kume H, Igawa Y, Homma Y. Incidence and risk factors of inguinal hernia after robot-assisted radical prostatectomy. *World J Surg Oncol.* 15, 61, 2017.
 28. Taguchi S, Buti S, Fukuhara H*, Otsuka M, Bersanelli M, Morikawa T, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? *PLoS One* 12: e0172341, 2017.

29. Kamei J, Yagihara Y, Kume H, Horiuchi T, Sato T, Nakagawa T, Fujimura T, Fukuhara H, Moriya K, Homma Y. Prevalence and characteristics of fecal antimicrobial-resistant *Escherichia coli* in a cohort of Japanese men undergoing prostate biopsy. *Int J Urol.* 24, 295-300, 2017.
30. Aizawa N, Ito H, Sugiyama R, Fujimura T, Fukuhara H, Kume H, Homma Y, Igawa Y. Effects of Sildenafil, a Phosphodiesterase Type 5 Inhibitor, on the Primary Single Afferent Activity of the Rat Bladder. *Low Urin Tract Symptoms.* 9, 57-61, 2017.
31. Nakagawa T, Taguchi S, Uemura Y, Kanatani A, Ikeda M, Matsumoto A, Yoshida K, Kawai T, Nagata M, Yamada D, Komemushi Y, Suzuki M, Enomoto Y, Nishimatsu H, Ishikawa A, Nagase Y, Kondo Y, Tanaka Y, Okaneya T, Hirano Y, Shinohara M, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder. *Urol Oncol.* 35, 457.e15-457.e21, 2017.
32. Naito A, Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Tabata M, Miyakawa J, Suzuki M, Nishimatsu H, Enomoto Y, Takahashi S, Okaneya T, Yamada D, Tachikawa T, Minowada S, Fujimura T, Fukuhara H, Kume H, Homma Y. Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder. *World J Urol.* 35, 97-103, 2017.
33. Makino K, Nakagawa T, Kanatani A, Kawai T, Taguchi S, Otsuka M, Matsumoto A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Biphasic decline in renal function after radical cystectomy with urinary diversion. *Int J Clin Oncol.* 22, 359-365, 2017.
34. Taguchi S, Fukuhara H*, Homma Y, Todo T. Current status of clinical trials assessing oncolytic virus therapy for urological cancers. *Int J Urol.* 24, 342-351, 2017.
35. Taguchi S, Fukuhara H*, Homma Y. Re: Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival: A. Abugharib, W. C. Jackson, V. Tumati, R. T. Dess, J. Y. Lee, S. G. Zhao, M. Soliman, Z. S. Zumsteg, R. Mehra, F. Y. Feng, T. M. Morgan, N. Desai and D. E. Spratt. *J Urol* 2017; 197: 662–668. *J Urol* 198, 212-214, 2017.

2016 年

36. Okegawa T, Itaya N, Hara H, Tambo M, Nutahara K : Epidermal growth factor receptor status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with docetaxel chemotherapy. *Int J Mol Sci* 17(12), 2016. pii: E2008.
37. Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K : Afatinib against esophageal or head-and-neck squamous cell carcinoma: Significance of activating oncogenic HER4 mutations in HNSCC. *Mol Cancer Ther* 15(8) : 1988-1997, 2016.
38. Kinoshita M, Higashihara E, Kawano H, Higashiyama R, Koga D, Fukui T, Gondo N, Oka T, Kawahara K, Rigo K, Hague T, Katsuragi K, Sudo K, Takeshi M, Horie S, Nutahara K : Technical

- evaluation: Identification of pathogenic mutations in PKD1 and PKD2 in patients with autosomal dominant polycystic kidney disease by next-generation sequencing and use of a comprehensive new classification system. *PLoS One* 11(11) : e0166288, 2016.
39. Ieda T, Muto S, Shimizu F, Taguri M, Yanada S, Kitamura K, Terai K, Saito K, Ogishima T, Nagata M, Ide H, Okegawa T, Wakumoto Y, Sakamoto Y, Tsujimura A, Yamaguchi R, Nutahara K, Horie S : Development and validation of a novel recurrence risk stratification for initial non-muscle invasive bladder cancer in Asia. *EBioMedicine* 12:98-104, 2016.
40. Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, Narita I, Nutahara K, Tsuchiya K, Tsuruya K, Kamura K, Nishio S, Suwabe T, Ubara Y, Ishimura E, Nakanishi K, Furukawa K, Kimura K, Matsuo S : Evidence-based clinical practice guidelines for polycystic kidney disease 2014. *Clin Exp Nephrol* 20(4) : 493-509, 2016.
41. Yamaguchi T, Okegawa T, Higashihara E, Nutahara K : Comparison of overall survival after nephron-sparing surgery and radical nephrectomy on the basis of preoperative renal function and tumor size. *J Nephrol Ther* 2016 6(5) doi: 10.4172/2161-0959.1000258.
42. Yamaguchi T, Okegawa T, Higashihara E, Nutahara K : Categorized preoperative estimated glomerular filtration rate as a criterion for choosing between radical or partial nephrectomy for renal tumor. *J Nephrol Ther* 2016 6(5) doi: 10.4172/2161-0959.1000259.
43. Yamada Y, Nakagawa T, Sugihara T, Horiuchi T, Yoshizaki U, Fujimura T, Fukuhara H, Urano T, Takayama K, Inoue S, Kume H, Homma Y. Prognostic value of CD66b positive tumor-infiltrating neutrophils in testicular germ cell tumor. *BMC Cancer* 16: 898, 2016.
44. Nozaki K, Kamiyo Y, Nakatsuka M, Azuma T, Nakagawa T, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Ishibashi Y, Homma Y. Computed tomography for the management of exit-site and tunnel infections in peritoneal dialysis patients. *Clin Nephrol.* 86, 328-332, 2016.
45. Aizawa N, Fukuhara H, Fujimura T, Homma Y, Igawa Y. Direct influence of systemic desensitization by resiniferatoxin on the activities of A δ - and C-fibers in the rat primary bladder mechanosensitive afferent nerves. *Int J Urol.* 23, 952-56, 2016.
46. Yamada Y, Takayama KI, Fujimura T, Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T, Fukuhara H, Homma Y, Inoue S. A novel prognostic factor TRIM44 promotes cell proliferation and migration and inhibits apoptosis in testicular germ cell tumor. *Cancer Sci.* 108, 32-41, 2016.
47. Ito H, Kamei J, Aizawa N, Fujita Y, Suzuki M, Fukuhara H, Fujimura T, Kojima T, Homma Y, Kubota Y, Ito M, Andersson KE, Igawa Y. Preventive effects of long-term caloric restriction on aging-related in vivo bladder dysfunctions and molecular biological changes in the bladder and dorsal root ganglia in rat. *J Urol.* 196, 1575-1583, 2016.

48. Taguchi S, Fukuhara H*, Morikawa T, Matsumoto A, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible? *Jpn J Clin Oncol.* 46, 1143-1147, 2016.
49. Taguchi S, Shiraishi K, Fukuhara H*, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y. Optimal timing of salvage radiotherapy for biochemical recurrence after radical prostatectomy: is ultra-early salvage radiotherapy beneficial? *Radiat Oncol.* 11, 102-107, 2016.
50. Niimi A, Suzuki M, Yamaguchi Y, Ishii M, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Akishita M, Homma Y. Sleep apnea and circadian extracellular fluid change as an independent factor for nocturnal polyuria. *J Urol.* 196, 1183-1189, 2016.
51. Taguchi S, Shiraishi K, Fukuhara H*, Nakagawa K, Morikawa T, Naito A, Kakutani S, Takeshima Y, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Homma Y. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer. *Int J Clin Oncol.* 21, 975-980, 2016.
52. Taguchi S, Kume H, Fukuhara H*, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Igawa Y, Homma Y. Symptoms at diagnosis as independent prognostic factors in retroperitoneal liposarcoma. *Mol Clin Oncol.* 4, 255-260, 2016.
53. Yamada Y, Fujimura T, Fukuhara H, Miyagawa J, Miyazaki H, Nakagawa T, Kume H, Homma Y. Measuring Contact Pressure of Lower Extremities in Patients Undergoing Robot-Assisted Radical Prostatectomy. *Urol Int.* 96, 268-273, 2016.
54. Fujimura T, Menon M, Fukuhara H, Kume H, Suzuki M, Yamada Y, Niimi A, Nakagawa T, Igawa Y, Homma Y. Validation of an educational program balancing surgeon training and surgical quality control during robot-assisted radical prostatectomy. *Int J Urol.* 23, 160-166, 2016.
55. Otsuka M, Taguchi S, Nakagawa T, Kawai T, Morikawa T, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Lower ureteral lesion is an independent predictor of intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma. *Urol Oncol.* 34, 59e9-13, 2016.
56. Taguchi S, Akamatsu N, Nakagawa T, Gono W, Kanatani A, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Homma Y. Sarcopenia Evaluated Using the Skeletal Muscle Index Is a Significant Prognostic Factor for Metastatic Urothelial Carcinoma. *Clin Genitourin Cancer.* 14, 237-243, 2016.
57. Aizawa N, Sugiyama R, Ichihara K, Fujimura T, Fukuhara H, Homma Y, Igawa Y. Functional roles of the bladder alpha1-adrenoceptors in the activation of single-unit primary bladder afferent activity in rats. *BJU Int.* 117, 993-1001, 2016.

58. Niimi A, Nomiya A, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y. Hydrodistension with or without fulguration of bladder lesions for interstitial cystitis: Long-term outcomes and prognostic predictors. *Neurourol Urodyn.* 35, 965-969, 2016.
59. Ito H, Aizawa N, Sugiyama R, Watanabe S, Takahashi N, Tajimi M, Fukuhara H, Homma Y, Kubota Y, Andersson KE, Igawa Y. Functional role of the TRPM8 ion channel in the urinary bladder assessed by conscious cystometry and ex vivo measurements of single-unit mechanosensitive bladder afferent activities in the rat. *BJU Int.* 117, 484-494, 2016.
60. Aizawa N, Gandaglia G, Hedlund P, Fujimura T, Fukuhara H, Montorsi F, Homma Y, Igawa Y. URB937, a peripherally-restricted inhibitor for fatty acid amide hydrolase, reduces prostaglandin E2-induced bladder overactivity and hyperactivity of bladder mechano-afferent nerve fibers in rats. *BJU Int.* 117, 821-828, 2016.
61. Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci.* 107, 1373-1379, 2016.
62. Hirata Y, Morino K, Suzuki T, Guo Q, Fukuhara H and Aihara K. System identification and parameter estimation in mathematical medicine: examples demonstrated for prostate cancer. *Quantitative Biology* 4, 13-19, 2016.

2015 年

63. Kondo T, Nakazawa H, Oya M, Kimura G, Fujii Y, Hatano T, Kawata N, Kume H, Morita M, Nakajima K, Ohno Y, Okegawa T, Takahashi S, Wakumoto Y, Horie S, Yamaguchi R, Saito K, Murakami M : Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib. *Jpn J Clin Oncol.* 45(3) : 274-280, 2015.
64. Higashihara E, Nutahara K, Okegawa T, Tanbo M, Hara H, Miyazaki I, Kobayashi K, Nitatori T : Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease. *Nephron* 129(4) : 253-262, 2015.
65. Higashihara E, Nutahara K, Okegawa T, Tanbo M, Mori H, Miyazaki I, Nitatori T, Kobayashi K : Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. *Clin Exp Nephrol* 19(4) : 746-752, 2015.
66. Fujimura T, Takahashi S, Kume H, Urano T, Takayama K, Yamada Y, Suzuki M, Fukuhara H, Nakagawa T, Inoue S, Homma Y. Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial. *BMC Cancer.* 15, 836, 2015.
67. Taguchi S, Fukuhara H*, Shiraishi K, Nakagawa K, Morikawa T, Kakutani S, Takeshima Y, Miyazaki H, Fujimura T, Nakagawa T, Kume H, Homma Y. Radical Prostatectomy versus

- External Beam Radiotherapy for cT1-4N0M0 Prostate Cancer: Comparison of Patient Outcomes Including Mortality. *PLoS One*. 10, e0141123, 2015.
68. Kamei J, Furuta A, Akiyama Y, Niimi A, Ichihara K, Fujimura T, Fukuhara H, Kume H, Homma Y, Igawa Y. Video-urodynamic effects of mirabegron, a β_3 -adrenoceptor agonist, in patients with low-compliance bladder. *Int J Urol*. 22, 956-961, 2015.
69. Taguchi S, Nakagawa T, Uemura Y, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Fujimura T, Fukuhara H, Kume H, Homma Y. Validation of major prognostic models for metastatic urothelial carcinoma using a multi-institutional cohort of the real world. *World J Urol*. 34, 163-171, 2016.
70. Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, Fukuhara H, Kume H, Igawa Y, Homma Y. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. *Int J Urol*. 22, 835-41, 2015.
71. Taguchi S, Nakagawa T, Matsumoto A, Nagase Y, Kawai T, Tanaka Y, Yoshida K, Yamamoto S, Enomoto Y, Nose Y, Sato T, Ishikawa A, Uemura Y, Fujimura T, Fukuhara H, Kume H, Homma Y. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of survival in patients with metastatic urothelial carcinoma: A multi-institutional study. *Int J Urol*. 22, 638-43, 2015.
72. Nishimatsu H, Suzuki E, Saito Y, Niimi A, Nomiya A, Fukuhara H, Kume H, Homma Y. Senescent Cells Impair Erectile Function through Induction of Endothelial Dysfunction and Nerve Injury in Mice. *PLoS One*. 10, e0124129, 2015.
73. Kume H, Kawai T, Nagata M, Azuma T, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Fukuhara H, Homma Y. Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. *Molecular and Clinical Oncology*. 3, 303-307, 2015.
74. Fujimura T, Yamada Y, Sugihara T, Azuma T, Suzuki M, Fukuhara H, Nakagawa T, Kume H, Igawa Y, Homma Y. Nocturia in men is a chaotic condition dominated by nocturnal polyuria. *Int J Urol*. 22, 496-501, 2015.
75. Kanatani A, Nakagawa T, Kawai T, Naito A, Sato Y, Yoshida K, Nozaki K, Nagata M, Yamada Y, Azuma T, Suzuki M, Fujimura T, Fukuhara H, Nishimatsu H, Kume H, Igawa Y, Homma Y. Adjuvant Chemotherapy Is Possibly Beneficial for Locally Advanced or Node-Positive Bladder Cancer. *Clin Genitourin Cancer*. 13, e107-112, 2015.
76. Ito H, Aizawa N, Fujita Y, Suzuki M, Fukuhara H, Homma Y, Kubota Y, Ito M, Andersson KE, Igawa Y. Long-term caloric restriction in rats may prevent age-related impairment of in vitro bladder function. *J Urol*. 193, 2123-30, 2015.
77. Kakutani S, Fukuhara H, Taguchi S, Nagata M, Niimi A, Hattori M, Miyazaki H, Fujimura T, Nakagawa T, Kume H, Igawa Y, Homma Y. Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. *Jpn J Clin Oncol*.

45, 281-5, 2015.

78. Aizawa N, Ito H, Sugiyama R, Fujimura T, Suzuki M, Fukuhara H, Homma Y, Igawa Y. Selective inhibitory effect of imidafenacin and 5-hydroxymethyl tolterodine on capsaicin-sensitive C-fibers of the primary bladder mechanosensitive afferent nerves in the rat. *J Urol.* 193, 1423-32, 2015.
79. Fukuhara H and Todo T. New generation of oncolytic herpes virus. *Current Cancer Therapy Reviews*, 11, 163-177, 2015.
80. Makino K, Kume H, Morikawa T, Niimi A, Fujimura T, Nakagawa T, Fukuhara H, Homma Y. Adenocarcinoma at anastomotic site of ureterosigmoidostomy potentially of urothelial origin spreading to the upper urinary tract. *Case Rep Urol.* 564082, 2015.

2014 年

81. Higashihara E, Nutahara K, Okegawa T, Shishido T, Tambo M, Kobayasi K, Nitadori T : Kidney volume and function in autosomal dominant polycystic kidney disease. *Clin Exp Nephrol* 18(1) : 157-165, 2014.
82. Kamiya N, Suzuki H, Nishimura K, Fujii M, Okegawa T, Matsuda T, Morita T, Takihana Y, Ozono S, Namiki M, Matsubara A, Ichikawa T, Miki T : Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model. *Jpn J Clin Oncol* 44(3) : 263-269, 2014.
83. Okegawa T, Higaki M, Matsumoto T, Kase H, Murata A, Noda K, Noda H, Asaoka H, Oshi M, Tomoishi J, Uchida H, Higashihara E, Nutahara K, Bone Metastasis Prostate Cancer Group : Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. *Anticancer Res* 34(8) : 4415-4420, 2014.
84. Okegawa T, Itaya N, Hara H, Tambo M, Nutahara K : Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer. *Anticancer Res* 34(11) : 6705-6710, 2014.
85. Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K, Nakatsura T : Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. *Oncol Rep* 32(5) : 1772-1778, 2014.
86. Tambo M, Okegawa T, Shishido T, Higashihara E, Nutahara K : Predictors of septic shock in obstructive acute pyelonephritis. *World J Urol* 32(3) : 803-811, 2014.
87. Fujita N, Okegawa T, Terado Y, Tambo M, Higashihara E, Nutahara K : Serum level and immunohistochemical expression of vascular endothelial growth factor for the prediction of postoperative recurrence in renal cell carcinoma. *BMC Res Notes* 7 : 369, 2014.

88. Higashihara E, Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi K, Nitadori T : Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? *Nephrol Dial Transplant* 29(9) : 1710-1719, 2014.
89. Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, Fujimura T, Homma Y, Kakimi K. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. *J Immunother Cancer*. 2, 30, 2014.
90. Yamada D, Matsushita H, Azuma T, Nakagawa T, Nagata M, Yamada Y, Suzuki M, Fujimura T, Fukuhara H, Kume H, Homma Y, Kakimi K. Granulocyte macrophage colony-stimulating factor as a predictor of the response of metastatic renal cell carcinoma to tyrosine kinase inhibitor therapy. *Mol Clin Oncol*. 2, 1023-1027, 2014.
91. Taguchi S, Fukuhara H*, Kakutani S, Takeshima Y, Miyazaki H, Suzuki M, Fujimura T, Nakagawa T, Igawa Y, Kume H, Homma Y. Risk factors for clinical metastasis in men undergoing radical prostatectomy and immediate adjuvant androgen deprivation therapy. *Asian Pac J Cancer Prev*. 15, 10729-33, 2014.
92. Taguchi S, Fukuhara H*, Azuma T, Suzuki M, Fujimura T, Nakagawa T, Ishikawa A, Kume H, Igawa Y, Homma Y. Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer. *BMC Urol*. 14, 81-86, 2014.
93. Sugihara T, Yasunaga H, Horiguchi H, Matsui H, Fujimura T, Nishimatsu H, Fukuhara H, Kume H, Yu C, Kattan MW, Kiyohide F, Homma Y. Robot-assisted versus other types of radical prostatectomy: population-based safety and cost comparison in Japan, 2012-2013. *Cancer Sci*. 105, 1421-1426, 2014.
94. Nishimatsu H, Kitamura Y, Yamada D, Nomiya A, Niimi A, Suzuki M, Fujimura T, Fukuhara H, Nakagawa T, Enomoto Y, Kume H, Igawa Y, Homma Y. Improvement of symptoms of aging in males by a preparation LEOPIN ROYAL containing aged garlic extract and other five of natural medicines - comparison with traditional herbal medicines (Kampo). *Aging Male*. 17, 112-116, 2014.
95. Sato YT, Fukuhara H*, Suzuki M, Fujimura T, Nakagawa T, Nishimatsu H, Kume H, Morikawa T, Fukayama M, Homma Y. Long-term results of radical prostatectomy with immediate adjuvant androgen deprivation therapy for pT3N0 prostate cancer. *BMC Urol*. 14, 13-18, 2014.
96. Kamei J, Nishimatsu H, Nakagawa T, Suzuki M, Fujimura T, Fukuhara H, Igawa Y, Kume H, Homma Y. Risk factors for septic shock in acute obstructive pyelonephritis requiring emergency drainage of the upper urinary tract. *Int Urol Nephrol*. 46, 493-497; 2014.

97. Teshima T, Takahashi S, Nagamoto S, Miyazaki H, Nakagawa T, Fujimura T, Fukuhara H, Kume H, Homma Y. Intrascrotal dedifferentiated leiomyosarcoma originating from dartos muscle. *Case Rep Urol.* 841929, 2014.
98. Mukaiyama Y, Suzuki M, Morikawa T, Mori Y, Takeshima Y, Fujimura T, Fukuhara H, Nakagawa T, Nishimatsu H, Kume H, Homma Y. Multiple primary malignant neoplasms of the glottis, renal pelvis, urinary bladder, oral floor, prostate, and esophagus in a Japanese male patient: a case report. *World J Surg Oncol.* 12, 294, 2014.

2013 年

99. Okegawa T, Ushio K, Imai M, Morimoto M, Hara T : Orphan nuclear receptor HNF4G promotes bladder cancer growth and invasion through the regulation of the hyaluronan synthase 2 gene. *Oncogenesis* 2 : e58, 2013.
100. Taguchi S, Nakagawa T, Hattori M, Niimi A, Nagata M, Kawai T, Fukuhara H, Nishimatsu H, Ishikawa A, Kume H, Homma Y. Prognostic Factors for Metastatic Urothelial Carcinoma Undergoing Cisplatin-based Salvage Chemotherapy. *Jpn J Clin Oncol.* 43, 923-928, 2013.
101. Nishimatsu H, Suzuki E, Nomiya A, Niimi A, Suzuki M, Fujimura T, Fukuhara H, Homma Y. Adrenomedullin and Angiopoietin-1 Additively Restore Erectile Function in Diabetic Rats: Comparison with the Combination Therapy of Vascular Endothelial Growth Factor and Angiopoietin-1. *J Sex Med.* 10, 1707-1709, 2013.
102. Yamada D, Nishimatsu H, Kumano S, Hirano Y, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Kume H, Homma Y. Reduction of prostate cancer incidence by naftopidil, an $\alpha 1$ -adrenoceptor antagonist and transforming growth factor- β signaling inhibitor. *Int J Urol.* 20, 1220-1227, 2013.
103. Fukuhara H. Report of the international journal of urology editorial board meeting 2013 in sapporo. *Int J Urol.* 20: 649-50, 2013.

2012 年

104. Higashihara E, Horie S, Muto S, Mochizuki T, Nutahara K : Renal disease progression in autosomal dominant polycystic kidney disease. *Clin Exp Nephrol* 16(4) : 622- 628, 2012.
105. Okegawa T, Itaya N, Hara H, Nutahara K, Higashihara E : Retroperitoneal laparoscopic single-site nephroureterectomy: Initial operative experience. *Asian J Endosc Surg* 5(4) : 164-167, 2012.
106. Okegawa T, Itaya N, Hara H, Nutahara K, Higashihara E : Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy. *Int J Urol* 19(8) : 778-782, 2012.
107. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators : Tolvaptan in patients with

- autosomal dominant polycystic kidney disease. *N Engl J Med* 367(25) : 2407-2418, 2012.
108. Habuchi T, Terachi T, Mimata H, Kondo Y, Kanayama H, Ichikawa T, Nutahara K, Miki T, Ono Y, Baba S, Naito S, Matsuda T : Evaluation of 2,590 urological laparoscopic surgeries undertaken by urological surgeons accredited by an endoscopic surgical skill qualification system in urological laparoscopy in Japan. *Surg Endosc* 26 (6) : 1656-1663, 2012.
109. Saito H, Matsuda T, Tanabe K, Kawauchi A, Terachi T, Nakagawa K, Iwamura M, Shigeta M, Tatsugami K, Ito A, Machida J, Kawakita M, Kinoshita H, Shinohara N, Ioritani N, Seki T, Arai Y; Japanese Society Of Endourology Laparoscopic Partial Nephrectomy Study Group, Watanabe S, Sazawa A, Nonomura K, Matsuura S, Kondo T, Kawauchi A, Nomoto T, Hamasaki T, Kondo Y, Tanaka K, Kobayashi K, Mita K, Nakagawa K, Yoshimura K, Sasamoto H, Kato T, Tomita Y, Kouda S, Makiyama K, Okegawa T, Terai A, Naya Y, Ujiie T, Nishimura K, Sakamoto W, Tsujihata M, Okasyo K, Okumura K, Zakoji H, Obara T, Habuchi T, Kan M, Tanimoto S, Inokuchi J, Seiji N, Takei F, Masumori N, Ito K, Asano T, Kameoka H, Narita M, Izaki H, Kanayama H, Inagaki T, Kobayashi M, Hosomi M, Ishizuka O, Takagi H, Yamamoto Y, Taguchi I, Kawabata G, Suenaga T, Kakehi Y: Surgical and oncologic outcomes of laparoscopic partial nephrectomy : a Japanese multi-institutional study of 1375 patients. *J Endourol* 26(6) : 652-659, 2012.
110. Miyazaki H, Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Homma Y. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer receiving zoledronic acid and docetaxel. *BJU Int.* 110, E520-525, 2012.
111. Nakamura M, Fujimura T, Nagata M, Hosoda C, Suzuki M, Fukuhara H, Enomoto Y, Nishimatsu H, Kume H, Igawa Y, Homma Y. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International index of erectile function-5 questionnaires. *Aging Male.* 15, 111-114, 2012.
112. Sugihara T, Yasunaga H, Horiguchi H, Nishimatsu H, Fukuhara H, Enomoto Y, Kume H, Ohe K, Matsuda S, Homma Y. Management trends, angioembolization performance and multiorgan injury indicators of renal trauma from Japanese administrative claims database. *Int J Urol.* 19, 559-563, 2012.
113. Fujimura T, Kume H, Nishimatsu H, Sugihara T, Nomiya A, Tsurumaki Y, Miyazaki H, Suzuki M, Fukuhara H, Enomoto Y, Homma Y. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score. *BJU Int.* 109, 1512-1516, 2012.
114. Nagata M, Sakurai-Yageta M, Yamada D, Goto A, Ito A, Fukuhara H, Kume H, Morikawa T, Fukayama M, Homma Y, Murakami Y. Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. *Int J Cancer* 130, 1329-1337, 2012.